Literature DB >> 20658797

The relationship between benzodiazepine use and traffic accidents: A systematic literature review.

Beitske E Smink1, Antoine C G Egberts, Klaas J Lusthof, Donald R A Uges, Johan J de Gier.   

Abstract

In many countries, benzodiazepines are the most commonly used and misused psychoactive medicinal drugs. Results of epidemiological studies investigating the association between benzodiazepine use and traffic accidents seem to be inconclusive or inconsistent at first sight. However, the outcome of epidemiological studies may be influenced by several methodological factors like study design, study population, exposure measurement, outcome definitions and possible confounders. Our objective was to conduct a systematic literature review of epidemiological studies that investigated the association between benzodiazepine use and traffic accidents, including related outcomes like culpability and injury or accident severity. We searched EMBASE, PubMed and Forensic Science Abstracts 3/0 (FORS) for references included in these databases at 1 June 2009 using the term 'benzodiazepines' in combination with 'driving performance' or 'accident risk' or 'traffic accident'. For inclusion in this review, the study design had to be comparative, include road users involved in accidents and provide specific data about benzodiazepines. Sixty-six studies were included in the review. The study populations varied from the general (driving) population, accident-involved road users with or without injury and persons admitted to a hospital to fatally injured accident-involved drivers. Exposure assessment was performed by using toxicological results, prescription data or questionnaires. The divergent study populations and comparison groups and the variety of methods used to express the outcome of interest hampered comparison between results. Evidence is growing that exposure to benzodiazepines is related to increased accident risk. The literature indicates that the greatest accident risk is associated with the use of long half-life benzodiazepines, increasing dosage and the first few weeks of use of benzodiazepines. Clear evidence of increased culpability associated with benzodiazepine use is scarce. More research has to be done to elucidate the relationship between benzodiazepine use and injury severity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658797     DOI: 10.2165/11533170-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  65 in total

Review 1.  Drugs and driving.

Authors:  J Michael Walsh; Johan J de Gier; Asbjørg S Christopherson; Alain G Verstraete
Journal:  Traffic Inj Prev       Date:  2004-09       Impact factor: 1.491

2.  Benzodiazepine use and the risk of motor vehicle crash in the elderly.

Authors:  B Hemmelgarn; S Suissa; A Huang; J F Boivin; G Pinard
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

3.  Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes.

Authors:  Jack E Gibson; Richard B Hubbard; Christopher J P Smith; Laila J Tata; John R Britton; Andrew W Fogarty
Journal:  Am J Epidemiol       Date:  2009-01-30       Impact factor: 4.897

4.  Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario.

Authors:  G Cimbura; D M Lucas; R C Bennett; R A Warren; H M Simpson
Journal:  J Forensic Sci       Date:  1982-10       Impact factor: 1.832

5.  Driving under the influence of drugs in Sweden with zero concentration limits in blood for controlled substances.

Authors:  Alan Wayne Jones
Journal:  Traffic Inj Prev       Date:  2005-12       Impact factor: 1.491

6.  The use of anti-depressants and benzodiazepines in the perpetrators and victims of accidents.

Authors:  D Currie; K Hashemi; J Fothergill; A Findlay; A Harris; I Hindmarch
Journal:  Occup Med (Lond)       Date:  1995-12       Impact factor: 1.611

7.  Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam.

Authors:  Ingebjørg Gustavsen; Jørgen G Bramness; Svetlana Skurtveit; Anders Engeland; Ineke Neutel; Jørg Mørland
Journal:  Sleep Med       Date:  2008-01-28       Impact factor: 3.492

Review 8.  Accident- and injury-related health-care utilization among benzodiazepine users and nonusers.

Authors:  G Oster; M W Russell; D M Huse; S F Adams; J Imbimbo
Journal:  J Clin Psychiatry       Date:  1987-12       Impact factor: 4.384

9.  Alcohol and drugs in fatally and non-fatally injured motor vehicle drivers in northern Sweden.

Authors:  Kristin Ahlm; Ulf Björnstig; Mats Oström
Journal:  Accid Anal Prev       Date:  2008-11-04

10.  Preliminary investigation of the association between psychotropic medication use and accidents, minor injuries and cognitive failures.

Authors:  Emma J K Wadsworth; Susanna C Moss; Sharon A Simpson; Andrew P Smith
Journal:  Hum Psychopharmacol       Date:  2003-10       Impact factor: 1.672

View more
  44 in total

1.  Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.

Authors:  Arnaud Panes; Antoine Pariente; Anne Bénard-Laribière; Régis Lassalle; Caroline Dureau-Pournin; Simon Lorrain; Marie Tournier; Annie Fourrier-Réglat
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-12-11       Impact factor: 5.270

Review 2.  Potentially Driver-Impairing Medications: Risks and Strategies for Injury Prevention.

Authors:  Timothy Ivers; Nicole D White
Journal:  Am J Lifestyle Med       Date:  2016-01-13

3.  On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

Authors:  Annemiek Vermeeren; Hong Sun; Eric F P M Vuurman; Stefan Jongen; Cees J Van Leeuwen; Anita C M Van Oers; John Palcza; Xiadong Li; Tine Laethem; Ingeborg Heirman; An Bautmans; Matthew D Troyer; Rebecca Wrishko; Jacqueline McCrea
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

4.  Benzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders.

Authors:  Greta A Bushnell; Tobias Gerhard; Stephen Crystal; Mark Olfson
Journal:  Pediatrics       Date:  2020-06-04       Impact factor: 7.124

Review 5.  Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators.

Authors:  Rakesh Jain; Shailesh Jain; Charles L Raison; Vladimir Maletic
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

Review 6.  Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.

Authors:  Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

7.  Increasing availability of benzodiazepines among people who inject drugs in a Canadian setting.

Authors:  Geoffrey Walton; Huiru Dong; M J Milloy; Kora DeBeck; Thomas Kerr; Evan Wood; Kanna Hayashi
Journal:  Subst Abus       Date:  2017-09-18       Impact factor: 3.716

Review 8.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

9.  Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study.

Authors:  Ludivine Orriols; Audrey Luxcey; Benjamin Contrand; Blandine Gadegbeku; Bernard Delorme; Aurore Tricotel; Nicholas Moore; Louis-Rachid Salmi; Emmanuel Lagarde
Journal:  Br J Clin Pharmacol       Date:  2016-09-09       Impact factor: 4.335

10.  Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.

Authors:  Anne Bénard-Laribière; Pernelle Noize; Elodie Pambrun; Fabienne Bazin; Hélène Verdoux; Marie Tournier; Bernard Bégaud; Antoine Pariente
Journal:  Eur J Clin Pharmacol       Date:  2016-03-29       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.